Overview

A Study of the Safety and Efficacy of Patients With Familial Hypercholesterolaemia Taking Colesevelam as add-on Therapy to Their Existing Medication

Status:
Completed

Trial end date:
2009-10-01

Target enrollment:

Participant gender:

Summary

This study is designed to assess whether colesevelam given as third line treatment added to a maximal tolerated and stable dose of a statin and ezetimibe is able to further decrease the level of LDL cholesterol in a safe and efficient manner in difficult to treat Familial Hypercholesterolaemia patients who are not at their target level of LDL cholesterol.

Phase:

Phase 4

Details

Lead Sponsor:

Genzyme, a Sanofi Company

Treatments:

Colesevelam Hydrochloride